Barry A. Siegel

Papers

Total Citations

H-Index

About

Barry A. Siegel is a pioneering figure in nuclear medicine and molecular imaging, with a career dedicated to advancing radiopharmaceutical production and clinical diagnostics. His key research areas encompass radiochemistry, PET imaging, and the optimization of radiotracer synthesis for oncology. Siegel’s most notable contribution is his seminal 1989 work on the elimination of contaminant kryptofix 2.2.2 in the routine production of 2-[18F]fluoro-2-deoxy-d-glucose (FDG), a critical step that ensured the purity and safety of this widely used PET tracer. This methodological refinement, cited 29 times, laid the groundwork for reliable FDG manufacturing, directly impacting countless clinical studies and patient scans worldwide. Beyond this, Siegel has been instrumental in translating radiochemical innovations into routine clinical practice, bridging the gap between laboratory research and patient care. His influence extends through numerous collaborative projects and leadership roles in professional societies, where he has shaped standards for radiopharmaceutical quality. With a legacy of enhancing the reproducibility and accessibility of PET imaging, Siegel remains a respected authority whose work continues to inform modern molecular imaging protocols and inspire new generations of radiochemists and nuclear medicine physicians.